DIRUI(SZ:300396)2022-12-07 08:41Group 1: Product Development and Sales Strategy - The company has obtained the medical device registration certificate for the fully automated chemiluminescence analyzer CM-240 from the Jilin Provincial Food and Drug Administration [2] - The sales strategy has been adjusted to increase bundled sales of instruments and reagents, leading to a 20% growth in reagent sales [2] - The company is focusing on enhancing its sales network and establishing overseas offices for product registration and certification [2] Group 2: Financial Performance - Revenue from reagent products reached 91 million yuan, a year-on-year increase of 20% [3] - Revenue from test paper products was 54 million yuan, with a year-on-year growth of 5% [3] - Instrument product revenue amounted to 196 million yuan, with blood cell reagent revenue exceeding 10 million yuan, reflecting a growth of over 40% [3] Group 3: Integration and Collaboration - The company has completed the business registration change for Ningbo Ruiyuan and is exploring cooperative strategies while maintaining competitive dynamics [2] - The collaboration will involve leveraging the company's instrument products to boost the sales of Ruiyuan's reagent products and vice versa [2]